Method development for quantification of quizartinib in rat plasma by liquid chromatography/tandem mass spectrometry for pharmacokinetic application.

about

Method development for quantification of quizartinib in rat plasma by liquid chromatography/tandem mass spectrometry for pharmacokinetic application.

Item

http://www.wikidata.org/entity/Q46544283

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Method development for quantif ...... r pharmacokinetic application.

@en

Method development for quantif ...... r pharmacokinetic application.

@nl

type

Item

label

Method development for quantif ...... r pharmacokinetic application.

@en

Method development for quantif ...... r pharmacokinetic application.

@nl

prefLabel

Method development for quantif ...... r pharmacokinetic application.

@en

Method development for quantif ...... r pharmacokinetic application.

@nl

P1476

Method development for quantif ...... or pharmacokinetic application

@en

P2093

Khalid A Al-Rashood

http://www.w3.org/2001/XMLSchema#string

Toqa El-Nahhas

http://www.w3.org/2001/XMLSchema#string

P2860

FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia.

Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.

FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia

Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.

A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.

Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies.

P31

scholarly article

P356

10.1002/BMC.4131

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

G A E Mostafa

Muzaffar Iqbal

Essam Ezzeldin

P577

2017-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29131376

http://www.w3.org/2001/XMLSchema#string